This technology is a method of bolstering immune defenses in intestinal tissue for the prevention and treatment of graft-versus-host disease, which is often caused by allogeneic hematopoietic stem cell transplantation.
Allogeneic hematopoietic stem cell (HPSC) transplantation, a common therapy for various genetic diseases and cancers, often results in potentially fatal complications, such as graft-versus-host disease (GVHD). It is thought that GVHD arises as a result of perturbations to the intestinal microbiota following allogeneic HPSC transplantation, leading to increased leukocyte activation that is characteristic of this complication. As such, a treatment that enhances intestinal resilience may prevent the onset of GVHD in transplant patients.
This technology utilizes analogs of glucagon-like peptide 2 (GLP-2) to bolster intestinal barrier function in hematopoietic stem cell transplant recipients in order to protect against GVHD. Using a specified dosing schedule that promotes tissue repair, the proposed therapeutic regimen significantly reduces intestinal permeability that contributes to inflammation and GVHD onset. With few off-target effects and a low toxicity profile, this technology may be used in conjunction with existing therapeutic regimens to greatly reduce the incidence of GVHD in HPSC transplantation recipients.
This technology has been validated in mouse models of allogeneic HPSC transplantation.
Patent Pending
CU19098
Licensing Contact: Jerry Kokoshka